Medicare rolls out $50 GLP-1 drug program
Digest more
CMS says the 18-month demonstration will expand access to select weight-loss drugs while the agency gathers data on uptake, outcomes and program operations.
For the first time ever, Medicare will cover drugs like Wegovy and Zepbound. But a strict BMI checklist and a 2027 deadline have some experts expressing concern.
The program is designed to expand access to a high-demand class of medications that have been financially out of reach for many.
